Filgrastim (r-metHuG-CSF): The first 10 years

Blood

Volumn 88, Issue 6, 1996, Pages 1907-1929

  Welte, Karl ^a   Gabrilove, Janice ^b   Bronchud, Miguel H ^b   Platzer, Erich ^b   Morstyn, George ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHENAZONE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GALLIUM NITRATE; GANCICLOVIR; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C; NAVELBINE; NITROSOUREA; PACLITAXEL; PENICILLIN DERIVATIVE; PHENOTHIAZINE; PIPERACILLIN; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOBRAMYCIN; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL MODEL; APLASTIC ANEMIA; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPTIC SHOCK; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0029815701     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.6.1907.bloodjournal8861907     Document Type: Review

References (176)

1. Weite K, Platzer E, Lu L. Gabrilove JL, Levi E, Mertelsmann R, Moore MA: Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 82:1526, 1985
2. Platzer E, Oez S, Weite K, Sendler A, Gabrilove JL, Mertelsmann R, Moore MA, Kalden JR: Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. Immunobiology 172:185, 1986
3. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, Barendt J, Platzer E, Moore MAS, Mertelsmann R, Weite K: Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 232:61, 1986
4. Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809, 1987
5. Gabrilove JL, Jakuboswki A, Fain K, Grous J, Scher H, Sternberg C, Yagoda A, Clarkson B, Bonilla MA, Oettgen HF, Alton K, Boone T, Altrock B, Weite K, Souza L: Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 82:1454, 1988
6. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, Oettgen HF, Alton K, Welle K, Souza L: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414, 1988
7. Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, Sheridan W, Metcalf D, Fox R: Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1:667, 1988
8. Ulich TR, del Castillo J, Souza L: Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia. Am J Pathol 133:630, 1988
9. Broxmeyer HE, Williams DE, Cooper S, Hangoc G, Ralph P: Recombinant human granulocyte-colony stimulating factor and recombinant human macrophagecolony stimulating factor synergize in vivo to enhance proliferation of granulocytemacrophage, erythroid, and multipotential progenitor cells in mice. J Cell Biochem 38:127, 1988
10. Welte K, Bonilla MA, Gillio AP, Boone TC, Potter GK, Gabrilove JL, Moore MA, O'Reilly RJ, Souza LM: Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 165:941, 1987
11. Gillio AP, Bonilla MA, Potter GK, Gabrilove JL, O'Reilly RJ, Souza LM, Welte K: Effects of recombinant human granulocyte-colony stimulating factor on hematopoietic reconstitution after autologous bone marrow transplantation in primates. Transplant Proc 19:153, 1987
12. Demetri GD, Griffin JD: Granulocyte colony-stimulating factor and its receptor. Blood 78:2791, 1991
13. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, Fowler KJ, Basu S, Zhan YF, Dunn AR: Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84:1737, 1994
14. Mempel K, Pietsch T, Menzel T, Zeidler C, Welte K: Increased serum levels of granulocyte colony-stimulating factor in patients with severe congenital neutropenia. Blood 77:1919, 1991
15. Cebon J, Layton JE, Maher D, Morstyn G: Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol 86:265, 1994
16. Hill CP, Osslund TD, Eisenberg D: The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci USA 90:5167, 1993
17. Inazawa J, Fukunaga R, Seto Y, Nakagawa H, Misawa S, Abe T, Nagata S: Assignment of the human granulocyte colony-stimulating factor receptor gene (CSF3R) to chromosome 1 at region p35-p34.3. Genomics 10:1075, 1991
18. Bashey A, Healy L, Marshall CJ: Proliferative but not nonproliferative responses to granulocyte colony-stimulating factor are associated with rapid activation of the p21ras/MAP kinase signalling pathway. Blood 83:949, 1994
19. Nicholson SE, Novak U, Ziegler SF, Layton JE: Distinct regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42,p44MAPK. Blood 86:3698, 1995
20. Tweardy DJ, Wright TM, Ziegler SF, Baumann H, Chakraborty A, White SM, Dyer KF, Rubin KA: Granulocyte colony-stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells. Blood 86:4409, 1995
21. Rauprich P, Kasper B, Tidow N, Weite K: The protein tyrosine kinase JAK2 is activated in neutrophils from patients with severe congenital neutropenia. Blood 86:4500, 1995
22. Bronchud MH, Potter MR, Morgenstern G, Blasco MJ. Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM: In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 58:64, 1988
23. Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L, Dexter TM: The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86:9499, 1989
24. Colgan SP, Gasper PW, Thrall MA, Boone TC, Blancquaert AM, Bruynickx WJ: Neutrophil function in normal and Chediak-Higashi syndrome cats following administration of recombinant canine granulocyte colony-stimulating factor. Exp Hematol 20:1229, 1992
25. Weisbart RH, Golde DW: Physiology of granulocyte and macrophage colony-stimulating factors in host defense. Hematol Oncol Clin North Am 3:401, 1989
26. Glaspy JA, Golde DW: Granuolocyte colony-stimulating factor (G-CSF): Preclinical and clinical studies. Semin Oncol 19:386, 1992
27. Yamamoto Y, Klein TW, Friedman H, Kimura S, Yamaguchi H: Granulocyte colony-stimulating factor potentates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunol Med Microbiol 7:15, 1993
28. Stevens P, Shatzer EM, Hanson ES, Allen RC: Pharmacodynamics of recombinant human G-CSF with respect to an increase of neutrophil oxidative metabolism. J Leukoc Biol 2:40, 1991
29. Ogawa M: Effects of hemopoietic growth factors on stem cells in vitro. Hematol Oncol Clin North Am 3:453, 1989
30. Morstyn G, Campbell L, Duḧrsen J, Souza LM, Alton NK, Villeval JL, Nicola NA, Boyd AW, Kannourakis G, Cebon J, Green M, Sheridan W, Metcalf D, Fox R: Clinical studies with granulocyte colony stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapy. Behring Inst Mitt 83:234, 1988
31. Morstyn G, Campbell L, Lieschke G, Layton JE, Maher D, O'Connor M, Green M, Sheridan W, Vincent M, Alton K, Souza L, McGrath K, Fox RM: Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 7:1554, 1989
32. Chatta GS, Price TH, Allen RC, Dale DC: Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 84:2923, 1994
33. Azuma J, Kurimoto T, Awata S, Sawamura A, Yoshida H, Seto Y, Mochizuki N, Kaneko T, Shimosaka A, Itoh H, Akahori H, Mikawa K, Sasahara K, Takaku F: Phase I study of KRN 8601 (rhG-CSF) in normal healthy volunteers: Safety and pharmacokinetics in single subcutaneous administration. Rinsho lyaku 5:2231, 1989
34. Morstyn G, Lieschke GJ, Cebon J, Duhrsen U, Villeval JL, Sheridan W, McGrath K, Layton JE: Early clinical trials with colony-stimulating factors. Cancer Invest 7:443, 1989
35. Young JD, Cheung EN, Tanaka H, Hasibeder H, Asano K, Shimosaka A: Bioavailability of subcutaneously administered non-glycosylated recombinant hG-CSF (Filgrastim) in normal and neutropenic rats and in humans. Proc Am Soc Clin Oncol 13:162, 1994 (abstr no. 443)
36. Layton JE, Hockman H, Sheridan WP, Morstyn G: Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-relaed control of a regulatory growth factor. Blood 74:1303, 1989
37. Tanaka H, Kaneko T: Pharmacokinetic and pharmacodynamic comparisons between human granulocyte colony-stimulating factor purified from human bladder carcinoma cell line 5637 culture medium and recombinant human granulocyte colony-stimulating factor produced in Escherichia coli. J Pharm Exp Ther 262:439, 1992
38. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE: Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 79:2849, 1992
39. Bronchud MH: Haemopoietic growth factors: Uses and misuses Eur J Cancer 31:813, 1995
40. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Grous J, Picozzi V, Rausch G, Smith R, Gandishar W, Yahanda A, Vincent M, Stewart M, Glaspy J: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325:164, 1991
41. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, Ewen C: Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319, 1993
42. Masuda N, Fukoka M, Furuse K: CODE chemotherapy with or without recombinant human granulocylte colony-stimulating factor in extensive-stage small cell lung cancer. Semin Oncol 49:19, 1992
43. Fukuoka M, Masuda N, Takada M, Kodama N, Kawahara M, Furuse K: Dose-intensive chemotherapy in extensive-stage small cell lung cancer. Semin Oncol 21:43, 1994
44. Lieschke GJ, Ramenghi U, O'Connor MP, Sheridan WP, Szer J, Morstyn G: Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Haematol 82:589, 1992
45. Lowenberg B, Touw IT: Hematopoietic growth factors and their receptors in acute leukemia. Blood 81:281, 1993
46. Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yokomaku S, Nakayama S, Yoshida Y, Miura AB, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871, 1990
47. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y, Furusawa S, Imai K, Takemoto Y, Miura Y, Teshima H, Hamajima N, Kohseisho Leukemia Study Group: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83:2086, 1994
48. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierce S, Freireich EJ, Deisseroth A, Keating M: Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671, 1994
49. Godwin JE, Kopecky KJ, Head DR, Hynes HE, Balcerzak SP, Appelbaum FR: A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia. A Southwest Oncology Group Study. Blood 86:434a, 1995 (abstr no. 1723, suppl 1)
50. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin J, Papa G, Noens L, Ho J, O'Brien C, Matcham J, Barge A: Results of a randomised, double-blind placebo controlled phase III study of rilgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Blood 86:267, 1995 (abstr no. 1053, suppl 1)
51. Giralt S, Escudier S, Kantarjian H, Heisseroth A, Freireich FJ, Andersson BS, O'Brien S, Andreeff M, Fisher H, Cork A, Hirsch-Ginsberg C, Trujillo J, Stass S, Champlin RE: Preliminary results of treatment with Filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 329:757, 1993
52. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678, 1995
53. Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430, 1992
54. Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PN, Wilson HE: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 4:295, 1986
55. Gaynor ER, Dahlberg S, Fisher RI: Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: An analysis of SWOG-8516 (INT 0067) - The national high priority lymphoma study - A randomized comparison of CHOP vs m-BA-COD vs ProMACE-CytaBOM vs MACOP-B. Proc Am Soc Clin Oncol 13:370, 1994 (abstr no. 1250)
56. Blayney DW, Williams S, Mortimer J, Tomita D, Horning S, Brown S. Wyres M: Neupogen® (r-metHuG-CSF) ameliorates neutropenia during CHOP chemotherapy. Proc Am Soc Clin Oncol 11:320, 1992 (ahstr no. 1088)
57. Meyer RM, Browman GP, Samosh ML, Benger AM, Bryant-Lukosius D. Wilson WEC, Frank GL, Leber BF, Sternbach MS, Foster GA, Skingley P, Levine MN: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386, 1995
58. Weite K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, Riehm H: A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 87:3143, 1996
59. Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, Lipp T, Busch FW, Schwonzen M, Heil G, Wandt H, Koch P, Kolbe K, Heyll A, Bentz M, Peters S, Diedrich H, Dethling J, Meyer P, Nowrousian MR, Löffler B, Weiss A, Kneha M, Föller A, Graf M, Hecht T: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial. Blood 86:444, 1995
60. Bezwoda WR, Seymour L, Dansey RD: high-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483, 1995
61. Schmidberger H, Hess CF, Hoffmann W, Reuss-Borst MA, Bamberg M: Granulocyte colony-stimulating factor treatment of leucopenia during fractionated radiotherapy. Eur J Cancer 29A:1927, 1993
62. MacManus MP, Harte RJ, Stranex S: Spontaneous regression of metastatic renal cell carcinoma following pallative irradiation of the primary tumour. Ir J Med Sci 163:461, 1994
63. MacManus MP, McCormick D, Trimble A, Abram WP: Value of granulocyte colony stimulating factor in radiotherapy induced neutropenia: Clinical and laboratory studies. Eur J Cancer 31A:302, 1995
64. Rule S, Davies J: Intermittent dosing of granulocyte colony stimulating factore (G-CSF) to facilitate palliative radiotherapy. Aust NZ J Med 24:402, 1994
65. Mäher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J, Toner G, Bradstock K, Leischke M, Cruickshank S, Tomita DK, Huffman EW, Fox RM, Morstyn G: Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 121:492, 1994
66. Mitchell PLR, Morland BJ, Dick G, Easles D, Meyer LC, Stevens MCG, Pinkerton CR: Clinical benefits and cost savings of interventional G-CSF therapy in patients with febrile neutropenia following chemotherapy. Blood 86:500a, 1995 (abstr no. 1989, suppl 1)
67. Bronchud MH: The importance of dose in cancer chemotherapy and the role of hematopoietic growth factors, in Morstyn G, Dexter TM (eds): Filgrastim in Clinical Practice. New York, NY, Marcel Dekker, 1994, p 131
68. Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM: The use of granulocyte colony-stimulating factor to increase the intesity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121, 1989
69. Roth BJ, Dreicer R, Einhorn LH, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ: Paclitaxel in previously untreated, advanced transitional cell carcinoma of the urethelium: A phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 13:230, 1994 (abstr 704)
70. Hutter H, Motzer R, Schwartz L, Fischer P, Majorin D, Scher H, Bosl G: Phase II trial in cisplatin-resistant germ cell tumor (GCT) patients (pts). Proc Am Soc Clin Oncol 13:A712, 1994
71. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Fiereabend C, Spriggs D: Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241, 1994
72. Link CJ Jr, Bicher A, Kohn EC, Christian MC, Davis PA, Adamo DO, Reed E, Sarosy GA: Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy. Blood 83:1188, 1994
73. Einhorn LH, Roth BJ, Ansari R, Dreicer R, Loehrer PJ: Vinbalstine, ifosfamide and gallium (VIG) combination chemotherapy in urothelial carcinoma. Proc Am Soc Clin Oncol 13:A702, 1994
74. Masuda N, Fukuoka M, Kudah S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T, Yoshikawa A, Kubo A, Matsuura E, Nitta T, Takifuji N, Terakawa K, Negoro S: Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12:1833, 1994
75. Taylor K, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B, Cabanillas FF, Hagemeister FB, Souza LM: Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 7:1791, 1989
76. Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, Layton JE, Green MD, Souza L, Fox RM: Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 2:891, 1989
77. Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A, Jacky E, Fey M, Platzer E: Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 12:1931, 1994
78. Kiesel S, Pezzutto A, Korbling M, Haas R, Schultz R, Hunstein W, Dorken B: Autologous peripheral blood stem cell transplantation: Analysis of autografted cells and lymphocyte recovery. Transplant Proc 21:3084, 1989
79. Schwinger W, Mache C, Urban C, Beaurfort E, Töglhofer W: Single dose of filgrastim (rhG-CSF) increases the number of hemopoietic progenitors in the peripheral blood of adult volunteers. Bone Marrow Transplant 11:489, 1993
80. Sato N, Sawada K, Takahashi TA, Mogi Y, Asano S, Koike T, Sekiguchi S: A time course study for optimal harvest of peripheral blood progenitor cells by granulocyte colony-stimulating factor in healthy volunteers. Exp Hematol 22:973, 1994
81. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Loffler H, Muller-Rochholtz W, Schmitz N: G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft. Br J Haematol 87:609, 1994
82. Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D: Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72:2074, 1988
83. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM: Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640, 1992
84. de Luca E, Sheridan WP, Watson D, Szer J, Begley CG: Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br J Cancer 66:893, 1992
85. Sheridan W, Begley G, Juttner C, de Luca E, To LB, Szer J, Maher D, Watson D, Grigg A, Cebon J, Morstyn G, McGrath K, Green M, Tomita D, Hoffman E, Fox RM: Effect of different does and schedules of r-metHuG-CSF (Filgrastim) on mononuclear cell and PBPC collections and haematopoietic recovery after high dose chemotherapy (HDC) and infusion of r-metHuG-CSF mobilized peripheral blood progentior cells (PBPC) without bone marrow. Blood 80:331a, 1992 (abstr no. 1315, suppl 1)
86. Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K, Williams B, Storb R, Thomas ED, Buckner CD: The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 81:1883, 1993
87. Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L, Blume KG: Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031, 1993
88. Schmilz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HMS, Link H, Zander A, Barge A, Borkett K: Filgrastim-mobilized peripheral blood progenitor cell transplantation in comparison with autologous bone marrow transplantation: Results of a randomized phase III trial in lymphoma patients. Lancet 347:353, 1996
89. Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, Bowers CE, Kronmueller N, Niemeyer R, Mclntyre W: Randomized study of growth factors post-peripheral-blood stemcell transplant: Neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 12:650, 1994
90. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS: Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial. J Clin Oncol 13:1323, 1995
91. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W: An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961, 1995
92. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 333:283, 1995
93. Bensinger W, Singer J, Appelbaum F, Lilleby K, Longin K, Rowley S, Clarke E, Clift R, Hansen J, Shields T, Storb R, Weaver C, Weiden P, Buckner CD: Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony stimulating factor. Blood 81:3158, 1993
94. Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg PL: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor. Blood 76:36, 1990
95. Kobayashi Y, Okabe T, Uzumaki H, Takaku F: Differentiation therapy of myelodysplastic syndrome by granulocyte colony stimulating factor. Clin Res 35:412a, 1988
96. Greenberg P, Taylor K, Larson R, Koeffler P, Negrin R, Saba H, Ganser A, Jacubowski A, Gabrilove J, Mufti G, Cruz J, Langley G, Vardiman J, Brown S, Blair C, Lebeau M: Comparison of four categorized risk scoring systems for analyzing outcome in GCSF-treated and observed patients with advanced myelodysplastic syndrome (MDS). Blood 84:25a, 1994 (abstr no. 88, suppl 1)
97. Kojima S, Fukuda M, Miyajima Y, Matsuyama T, Horibe K: Treatment of aplastic anemia in children with recombinant human granulocyte colony-stimulating factor. Blood 77:937, 1991
98. Sonoda Y, Yashige H, Fujii H, Tsuda S, Mackawa T, Misawa S, Abe T: Bilineage response in refractory aplastic anemia patients following long-term administration of recombinant human granulocyte colony-stimulating factor. Eur J Haematol 48:41, 1992
99. Welte K, Dale D: Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol 72:158, 1966
100. Dale DC, Hammond WP 4th: Cyclic neutropenia: A clinical review. Blood Rev 2:178, 1988
101. Bonilla MA, Gillio AP, Ruggeiro M, Kernan NA, Brochstein JA, Abboud M, Fumagalli L, Vincent M, Gabrilove JL, Welte K, Souza LM, O'Reilly RJ: Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 320:1574, 1989
102. Hammond WP 4th, Price TH, Souza LM, Dale DC: Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 320:1306, 1989
103. Jakubowski AA, Souza L, Kelly F, Fain K, Budman D, Clarkson B, Bonilla MA, Moore MA, Gabrilove J: Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 320:38, 1989
104. Welte K, Zeidler C, Reiter A, Muller W, Odenwald E, Souza L, Riehm H: Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 75:1056, 1990
105. Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, Wang W, Jakubowski A, Winton E, Lalezari P, Robinson W, Glaspy JA, Emerson S, Gabrilove J, Vincent M, Boxer LA: A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (Filgrastim) for treatment of severe chronic neutropenia. Blood 81:2496, 1993
106. Bonilla MA, Dale D, Zeidler C, Last L, Reiter A, Ruggeiro M, Davis M, Koci B, Hammond W, Gillio A, Welte K: Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 88:723, 1994
107. Gilman PA, Jackson DP, Guild HG: Congenital agranulocytosis: Prolonged survival and terminal acute leukemia. Blood 36:576, 1970
108. Rosen RB, Kang SJ: Congenital agranulocytosis terminating in acute myelomonocytic leukemia. J Pediatr 94:406, 1979
109. Dong F, Brynes R, Tidow N, Weite K, Löwenberg B, Touw IP: Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 333:487, 1995
110. Touw IP, de Koning JP, Löwenberg B, Dong F: Defective G-CSF receptors in severe congenital neutropenia (SCN) associated with progression towards MDS and AML. Blood 86:26a, 1995 (abstr no. 93, suppl 1)
111. Kalra R, Dale D, Freedman M, Bonilla MA, Weinblatt M, Ganser A, Bowman P, Abish S, Priest J, Oseas RS, Olson K, Paderanga D, Shannon K: Monosomy and activating RAS mutations accompany malignant transformation in patients with congential neutropenia. Blood 86:4579, 1995
112. De Marais PL, Pitrak DL, Bak PM, Novak RM, Heynen CA, Maney PJ, Holzer TJ: Altered expression of neutrophil (PMNL) surface markers in AIDS. Int Conf AIDS 8:PoA2004, 1992
113. Pitrak DL, Bak PM, De Marais P, Novak RM, Andersen BR: Depressed neutrophil superoxide production in human immunodeficiency virus infection. J Infect Dis 167:1406, 1993
114. Miles SA, Mitsuyasu RT, Moreno J, Baldwin G, Alton NK, Souza L, Glaspy JA: Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 77:2109, 1991
115. Jacobsen MA, Stanley HD, Heard SE: Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS 6:515, 1992
116. Hermans P, Franchioly P, Thioux C, Gray S, Vannerom H, Clumeck N: Granulocyte-colony stimulating factor (G-CSF [filgrastim]) for treatment of neutropenia in patients with AIDS. Int AIDS Conf 9:65a, 1993
117. Balbiano R, Degioanni M, Valle M, Crivelli P, Bordino C. Mastinu A, Biglino A: Prevention of severe neutropenia in AIDS patients with intermittent, low-dose G-CSF (filgrastim). Int Conf AIDS 10:223, 1994 (abstr no. PB0323)
118. Goldstein D, Newell M, Milliken S, Lewis C, Hoy J, Thomson B, Dolan G, Ryan S, Sarr A, Cooper DA: Filgrastim, CEOP and antiretroviral therapy in HIV-related non-Hodgkins lymphoma (NHL). Annu Conf Australas Soc HIV Med 6:167, 1994
119. Foster PF, Mital D, Sankary HN, McChesney LP, Marcon J, Koukoulis G, Kociss K, Leurgans S, Whiting JF, Williams JW: The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation 59:1557, 1995
120. Polak-Wyss A: Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Candida infections in normal and immunosuppressed mice. Mycoses 34:109, 1991
121. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ: Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 61:1185, 1993
122. Hartung T, Docke WE, Gantner F, Krieger G, Sauer A, Stevens P, Volk HD, Wendel A: Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85:2482, 1995
123. Bone RC: The pathogenesis of sepsis. Ann Intern Med 115:457, 1991
124. Zimmerman GA, Renzetti AD, Hill HR: Functional and metabolic activity of granulocytes from patients with adult respiratory distress syndrome. Am Rev Res Dis 127:290, 1983
125. Rinaldo JE, Borovetz H: Deterioration of oxygenation and abnormal lung microvascular permeability during resolution of leukopenia in patients with diffuse lung injury. Am Rev Respir Dis 131:579, 1985
126. Bedford Russell AR, Davies EG, Gibson FM, Gordon-Smith EC: The in vitro effects of granulocyte and granulocyte-macrophage colony-stimulating factor on interleukin-3 dependent proliferation of human neonatal circulating progenitor cells. Pediatr Res 37:630, 1995
127. Gillan ER, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS: A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: Significant induction of peripheral and bone marrow neutrophilia. Blood 84:1427, 1994
128. Bedford Russell AR, Davies EG, Ball SE, Gordon-Smith EC: Granulocyte colony-stimulating factor treatment for neonatal neutropenia. Arch Dis Child 72:F53, 1995
129. Sprikkelman A, de Wolf JTM, Vellenga E: The application of hematopoietic growth factors in drug-induced agranulocytosis: A review of 70 cases. Leukemia 8:2031, 1994
130. + T cell-mediated leukopenia of Felty's syndrome successfully treated with granulocyte-colony-stimulating factor and methotrexate. Arthritis Rheum 37:298, 1994
131. Decoster G, Rich W: Tolerability profile of r-metHuG-CSF (G-CSF NEUPOGEN®). Eur J Cancer 27:233, 1991 (abstr 1428, suppl 2)
132. Decoster G, Rich W, Brown SL: Safety profile of Filgrastim (r-metHuG-CSF), in Morstyn G, Dexter TM (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice. New York, NY, Marcel Dekker, 1994, p 267
133. Sakamaki S, Matsunaga T, Hirayama Y, Kuga T, Niitsu Y: Haematological study of healthy volunteers 5 years after G-CSF. Lancet 346:1432, 1995
134. Lyman GH, Lyman CG, Sanderson RA, Balducci L: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst USA 85:488, 1993
135. Nichols CR, Fox EP, Roth BJ, Williams SD, Loehrer PJ, Einhorn LH: Incidence of neutropenic fever in patients with standard-dose combination chemotherapy for small cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 12:1245, 1994
136. Zagonel V, Babare R, Merola MC, Talamini R, Lazzarini R, Tirelli U, Carbone A, Monfardini S: Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphomas treated with combination chemotherapy. Ann Oncol 5:S127, 1994
137. Asano S: Human granulocyte colony-stimulating factor: Its basic aspects and clinical applications. Am J Ped Hematol Oncol 13:400, 1991
138. Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamoto O, Hirata Y, Kubota N, Oheda M, Nomura H, Ono M: Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 319:415, 1986
139. Brown TD, Tangen C, Fleming T, Macdonald J: A phase II trial of Taxol and granulocyte colongy stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 12:592a, 1993
140. Caldas C, McGuire WP: Paclitaxel (Taxol) therapy in ovarian carcinoma. Semin Oncol 20:50, 1993
141. Gridelli C, DePlacido S, Pepe R, Incoronato P, Airoma G, Rossi A, Palazzolo G, Bianco AR: Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. Eur J Cancer 29A:1729, 1993
142. Kohn E, Reed E, Link C, Christian M, Davis P, Sarosy G: A pilot study of Taxol, cisplatin, cyclophosphamide, and G-CSF in newly diagnosed stage III/IV ovarian cancer patients. Proc Am Soc Clin Oncol 12:814a, 1993
143. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943, 1993
144. Rowinsky ED, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010, 1993
145. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, TzyJyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F, Kelsen D: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499, 1993
146. Crawford J, O'Rourke MA: Vinorelbine (Navelbine)/carboplatin combination therapy: Dose intensification with granulocyte colony-stimulating factor. Semin Oncol 21:73, 1994
147. Peters WP, Rosner G, Vredenburg J, Meisenberg B, Gilbert C, Kurtzberg J: Comparative effects of granulocyte macrophage colony stimulating factor (GM-CSF) and granulocyte-colony stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 81:1709, 1993
148. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, Gooley T, Lynch M, Higano T, Klarnet J, Chauncey T, Storb R, Buckner CD: Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87:825, 1994
149. Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, Margolin KA, Woo D, Niland JC, Forman SJ: High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 12:2176, 1994
150. Faucher C, le Corroller AG, Biaise D, Novakovitch G, Manonni P, Moatti JP, Maraninchi D: Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: Clinical assessment and cost-effectiveness. Bone Marrow Transplant 14:895, 1994
151. Weaver CH, Buckner CD, Longin K, Appelbaum FR, Rowley S, Lilleby K, Miser J, Storb R, Hansen JA, Bensinger W: Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 82:1981, 1993
152. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655, 1995
153. Sheridan WP: Cytokine-only approaches to mobilization of progenitor cells, in Morstyn G, Sheridan WP (eds): Cell Therapy. Cambridge, UK, Cambridge University, 1996, p 146
154. Mueller BU, Jacobsen F, Butler KM, Husson RN, Lewis LL, Pizzo PA: Combination treatment as azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection. J Pediatr 121:797, 1992
155. Miles SA, Mitsuyasu RT, Lee K, Moreno J, Alton K, Egrie JC, Souza L, Glaspy JA: Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection. Blood 75:2137, 1990
156. Clumeck N, Wit SD, Hermans P, Franchioly P, Sommereijns B: Recombinant granulocyte colony-stimulating factor (rG-CSF) in HIV patients with zidovudine related neutropenia. J Nutr Sci Vitaminol 353, 1992 (special)
157. De Wit S, Rahir F, Franchioly P, Sommereijns B, Clumeck N: Recombinant granulocyte colony-stimulating factor (rG-CSF) in HIV patients (p) with zidovudine (Z) related neutropenia. Int AIDS Conf 7:44a, 1991
158. Wolf E, Hartl H, Poppinger H, Jaegel-Guedes E, Jaegar H: G-CSF given to severely ill patients in a community-based setting. Filgrastim improves white blood cell counts in HIV-related granulocytopenia - No lasting decline in thrombocytes. Int AIDS Conf 9:509a, 1993
159. Gute P, Staszewski S, Hoika R, Kober A, Hoelzer D, Heim EB: Efficacy and optimum dose of r-Hu granulocyte stimulating factor (G-CSF) in the treatment of AIDS-associated granulocytopenia. Int AIDS Conf 8:B213, 1992
160. Sloand E, Kumar PN, Pierce PF: Chemotherapy for patients with pulmonary Kaposi's sarcoma: Benefit of filgrastim (G-CSF) in supporting dose administration. South Med J 86:1219, 1993
161. Means RT, Sandidge DR, Rankin KM, Robichaux MR: Treatment of phenothiazine-induced agranulocytosis with recombiant granulocyte colony-stimulating factor. Am J Hematol 41:296, 1992
162. Hunt KA, Resnick MP: Clomipramine-induced agranulocytosis and its treatment with G-CSF. Am J Psychiatry 150:522, 1993
163. Patton WN, Holyoake TL, Yates JM, Broughton BJ, Franklin IM: Accelerated recovery from durg-induced agranulocytosis following G-CSF therapy. Br J Haematol 80:564, 1992
164. Teitelbaum A, Bell AJ, Brown SL: Filgrastim (r-metHuG-CSF) reversal of drug-induced agranulocytosis. Am J Med 95:245, 1993
165. Yokoyama K, Sato T, Nakajima S, Chino M, Komatsumoto S, Nara M, Okamoto S: Successful treatment of methimazole-induced agranulocytosis by granulocyte colony-stimulating factor. Am J Hematol 40:76, 1992
166. Gullion G, Yeh H-S: Treatment of clozapine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor. J Clin Psychiatry 55:401, 1994
167. Weide GR, Koppler H, Heymanns J, Pfluger KH, Havemann K: Successful treatment of clozapine induced granulocytosis with granulocyte-colony stimulating factor (G-CSF). Br J Haematol 80:557, 1992
168. Muroi K, Ito M, Sasaki R, Suda T, Sakamoto S, Miura Y: Treatment of drug-induced agranulocytosis with granulocyte-colony stimulating factor. Lancet 2:55, 1989
169. Magner JA, Snyder DK: Methimazole-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 4:295, 1994
170. Ruiz-Irastorza G, Alonso JJ, Iglesias JJ, Aguirre C: Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine. Acta Haematol 91:106, 1994
171. Yoshioka K: Combined therapy of G-CSF and prednisolone for neutropenia in a patient with Felty's syndrome. Am J Hematol 48:131, 1995
172. Graham KE, Coodley GO: A prolonged use of granulocyte colony stimulating factor in Felty's syndrome. J Rheumatol 22:174, 1995
173. Fohlman J, Höglund M, Bergmann S: Successful treatment of chronic wound infection in neutropenia and rheumatoid arthritis with filgrastim (rhG-CSF). Ann Hematol 69:153, 1994
174. Kondo H, Date Y, Sakai Y, Akimoto M: Effective simultaneous rhG-CSF and methylprednisolone "pulse" therapy in agranulocytosis associated with systemic lupus erythematosus. Am J Hematol 46:157, 1994
175. Miles S: Use of Filgrastim (r-metHuG-CSF) in human immunodeficiency virus infection, in Morstyn G, Dexter TM (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice. New York, NY, Marcel Dekker, 1994, p 117
176. Osslund T, Boone TC: Biochemistry and structure of Filgrastim (r-metHuG-CSF), in Morstyn G, Dexter TM (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice. New York, NY, Marcel Dekker, 1994, p 23